Cancer Vaccine Launch Pad (CVLP) Update
Date: 26 November 2025
The Cancer Vaccine Launch Pad (CVLP), established by NHS England, facilitates access for cancer patients across the country to cancer vaccine and immunotherapy trials, by identifying and referring suitable patients at scale and supporting tumour tissue processing. It is a high priority project and is a key part of the landmark strategic partnership between UK Government, NHS England and BioNTech. The CVLP network consists of over 77 NHS Trusts, and to date has supported 5 research trials. We are currently setting up two new studies: ROSETTA Lung-02 in non-small cell lung cancer and ROSETTA Breast-01 in triple negative breast cancer.
Due to the CVLP’s unique nature, specific advice is being provided for NHS Trusts on how to setup as a CVLP site and add new trials. The CVLP is a non-interventional platform study, and so the setup process only needs to be completed once when the Trust first joins the CVLP. To add new trials, a simple process has been created where the relevant clinical team attends a training session on the new trial, and any amendments to finances and targets are confirmed via email.
If there are periods of inactivity at a Trust where they are not supporting any trials, sites can amend their study status as ‘suspended’ in LPMS. The status can be updated back to ‘recruiting’ when recruitment recommences. As Capacity and Capability data is only collected once during the initial setup, marking the study as suspended in LPMS will not reset the timeline for this data. This means the original site setup timelines will be retained, provided the site is not deleted from the system and site setup dates are not amended.
If you have any questions, please contact Molly Obadiah, Programme Manager at NHS England (molly.obadiah1@nhs.net).